An in vitro nucleoside analog screening method for cancer gene therapy

Cell Biology and Toxicology

Volumn 12, Issue 4-6, 1996, Pages 345-350

  Evrard, A ^a   Vian, L ^a   Aubert, C ^b   Cano, J P ^a  

^a UNIV MONTPELLIER   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

cell cultures; gene therapy; nucleoside analog; thymidine kinase

Indexed keywords

ACICLOVIR; BROXURIDINE; EDOXUDINE; FLOXURIDINE; FLUOROURACIL; GANCICLOVIR; IDOXURIDINE; NUCLEOSIDE ANALOG; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; CANCER; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCREENING;

3T3 CELLS; ACYCLOVIR; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; GANCICLOVIR; GENE THERAPY; MICE; NEOPLASMS, EXPERIMENTAL; NUCLEOSIDES; SIMPLEXVIRUS; THYMIDINE KINASE; TOXICITY TESTS; TRANSFECTION;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0029806334     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00438169     Document Type: Conference Paper

References (16)

1. Balzarini J, Morin KW, Knaus EE, Wiebe LI, De Clercq E. Novel (E)-5-(2-iodovinyl)-2′-desoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors. Gene Ther. 1995;2:317-22.
2. Chen SH, Li Chen XH, Wang Y et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA. 1995;92:2577-81.
3. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 1995;2:702-9.
4. Culver K, Ram Z, Walbridge S, Hiroyuki I, Oldfield E, Blaese R. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-2.
5. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Ther. 1995;2:235-44.
6. Ezzedine ZD, Martuza RL, Platika D et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of herpes simplex virus thymidine kinase gene. New Biol. 1991;3:608-14.
7. Freeman SM, Abboud CN, Warthenby KA et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-83.
8. Huber BE, Richards CA, Krentisky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039-43.
9. Kulikowski T. Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogs. A review. Pharm World Sci. 1994;16:127-38.
10. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276-81.
11. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-87.
12. Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology. 1995;22:118-23.
13. Smith KO, Galoway KS, Kennel WL. A new nucleoside analog, 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1982;22:55-61.
14. Takamiya Y, Short M, Moolten F et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg. 1993;79:104-10.
15. Valère T. Thérapie génique: le point sur les essais cliniques. Médecine/Sciences. 1996;10:73-93.
16. Wu JK, Cano WG, Meylaerts SAG, Qi P, Vrionis F, Cherington V. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery. 1994;35:1094-102.